Two main categories of ADHD medication
ADHD medications fall into two broad categories: stimulants and non-stimulants. Both are well-studied, and the 2021 World Federation of ADHD Consensus Statement (Faraone et al.) confirms medication as a first-line treatment with strong evidence of effectiveness. Understanding the basics helps you have better conversations with your prescriber.
Stimulant medications
Stimulants are the most commonly prescribed and most effective ADHD medications for most people. They work by increasing dopamine and norepinephrine availability in the prefrontal cortex, which improves attention, impulse control, and executive function.
There are two main types:
- Methylphenidate-based (Ritalin, Concerta, Focalin): Available in immediate-release (about 3-4 hours) and extended-release (8-12 hours) forms.
- Amphetamine-based (Adderall, Vyvanse, Dexedrine): Also available in short and long-acting versions. Vyvanse is a prodrug, meaning it converts to its active form in the body, which creates a smoother onset.
Finding the right stimulant and dose is individual. Some people respond well to methylphenidate and poorly to amphetamines, or vice versa. It often takes several tries to find the right fit, and that's normal, not a sign that medication isn't for you.
Non-stimulant medications
Non-stimulants are used when stimulants cause intolerable side effects, when there's a history of substance use concerns, or as add-ons to stimulants. They include:
- Atomoxetine (Strattera): A norepinephrine reuptake inhibitor. Takes 4-6 weeks to reach full effect, unlike stimulants which work the same day. Provides 24-hour coverage.
- Guanfacine (Intuniv) and Clonidine (Kapvay): Alpha-2 agonists, originally blood pressure medications. Helpful for impulsivity, emotional regulation, and sleep problems. Sometimes combined with stimulants. Learn more about guanfacine for ADHD. Clonidine also comes as Onyda XR, an extended-release liquid approved in 2024 for ages 6 and up, taken at bedtime.
- Viloxazine (Qelbree): A newer option, a norepinephrine reuptake inhibitor with serotonin modulating activity.
- Centanafadine (Simtriyo): Approved by the FDA in July 2026 for adults and children 6 and older. It blocks reuptake of norepinephrine, dopamine, and serotonin, and carries a boxed warning about suicidal thoughts in children 6 to 12. See our centanafadine guide.
What to expect when starting medication
Stimulants typically produce noticeable effects on the first day, though the right dose may take weeks to dial in. Common early side effects include reduced appetite, difficulty sleeping, dry mouth, and sometimes increased anxiety. Most side effects diminish within the first few weeks.
For young children: in June 2025 the FDA required all extended-release stimulant labels to state that these products are not indicated for children under 6, because children that age have higher drug exposure and more side effects, including weight loss, at the same dose. If your child is under 6, talk to their prescriber about the options that fit that age.
A good prescriber will start at a low dose and increase gradually ("start low, go slow"). They should check in regularly during the titration period. If a prescriber hands you a prescription and says "see you in three months," consider finding someone who manages ADHD medication more actively.
Medication is a tool, not a cure
For people who respond well, medication can meaningfully reduce core ADHD symptoms. It makes it easier to implement strategies like focus techniques, task batching, and environmental design. It doesn't automatically create habits, fix relationships, or organize your apartment. Think of it as raising the floor of your executive function so that strategies actually work.
Many adults benefit from combining medication with therapy, particularly CBT adapted for ADHD. Safren et al. (2010) in JAMA found that, for adults already on medication, adding CBT reduced symptoms more than adding relaxation training and education.
Talking to your prescriber
Track how your medication affects you. Note energy levels, focus duration, mood, appetite, and sleep quality at different times of day. This information helps your prescriber make better adjustments. A simple daily log works better than trying to remember how the past month went during a 15-minute appointment.
References
- Faraone, S.V. et al. (2021). World Federation of ADHD International Consensus Statement. Neuroscience & Biobehavioral Reviews, 128, 789-818.
- Safren, S.A. et al. (2010). CBT for medication-treated adults with ADHD. JAMA, 304(8), 875-880.
- FDA requires new label warning for extended-release stimulants in children under 6 (June 2025). Psychiatric Times.
- FDA approves centanafadine (Simtriyo) for ADHD (July 2026). HCPLive.